Molica M, Breccia M, Colafigli G. Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. Br J Haematol. 2018; 181(2):275-278. https://doi.org/10.1111/bjh.14560 PubMed Google Scholar

Chung HJ, Hur M, Yoon S. Performance evaluation of the QXDx BCRABL %IS droplet digital PCR assay. Ann Lab Med. 2020; 40(1):72-75. https://doi.org/10.3343/alm.2020.40.1.72 PubMed PubMed Central Google Scholar In 2013, the ELN incorporated molecular monitoring using standardized real-time quantitative polymerase chain reaction (qRT-PCR) analysis into their recommendations for the management of CML. 26 An optimal response was BCR-ABL1≤10%, ≤1% and ≤0.1% at 3, 6 and 12 months of TKI therapy. Treatment failure was defined as BCR-ABL1>10% at 6 months and >1% at 12 months. These recommendations were based on strong evidence collected over many years 27-35 and subsequent studies consolidated the recommendations. 36-41 The importance of a one-log reduction of BCR-ABL1 by 3 months and two-log reduction by 6 months for progression- free survival was reported as early as 2003. 28 , 29 The equivalent BCR-ABL1 transcript values on the IS are 10% and 1%, respectively. An update of molecular data generated in the IRIS trial was published in 2010, and used to examine the prognostic significance of early molecular response. 30 Landmark analyses of BCR-ABL1 values at 6, 12 and 18 months of imatinib therapy established that event-free survival was inferior for patients with >10% at 6 months and >0.1% at 12 and 18 months. Progression to accelerated phase or blast crisis and overall survival were inferior for patients with BCR-ABL1>10% at 6 months, and >1% at 12 and 18 months. 30 In 2012, Hanfstein et al. 31 and Marin et al. 32 confirmed the strong association between BCR-ABL1 values at 3, 6 and 12 months and outcome. Marin et al. reported that the BCR-ABL1 value at 3 months was the only requirement for predicting outcome for patients treated with a TKI. 32 Furthermore, a BCRABL1 value of ≤0.61% at 3 months was highly predictive of subsequent undetectable BCR-ABL1. The cumulative incidence of undetectable BCR-ABL1 at 8 years for patients with BCR-ABL1≤0.61% was 84.7% whereas it was 1.5% for those with >0.61% ( P<0.001). 32 This study highlighted the importance of rapid leukemic clearance for a subsequent DMR. If an ‘Authorised Consignor’ using the Simplified procedure is making the declaration, then control result ‘A3’ will be required. Nimrod MRA4 First Flight". Defence Procurement Agency. 20 September 2005. Archived from the original on 12 October 2005. We included all patients diagnosed with CML in chronic phase, treated with TKI from January 2000 until December 2015, who achieved sustained MR3 (sMR3). We excluded patients treated with chemotherapy and/or stem cell transplantation before TKI. TKI were commenced at standard doses and may have been dose reduced subsequently to manage adverse events. Because some of the patients were treated prior to the availability of second-generation TKI, doses of imatinib > 400 mg daily (HD) were prescribed for less than optimal responses in 15% of patients. Episode of noncompliance with treatment was recorded in our database when patients admitted to taking less than 100% of the prescribed therapy. The data cut-off was 31 October 2017. This retrospective observational study was approved by the research ethics committee, and all patients gave written informed consent for their data to be stored and analyzed in our institutional database. Response definitions

Enter the code for the office of destination in the format ‘2a country+6nOffice identifier’ for example, GB000051. Ross DM, Branford S.. Minimal residual disease: the advantages of digital over analog polymerase chain reaction. Leuk Lymphoma. 2011; 52(7):1161-1163. https://doi.org/10.3109/10428194.2011.580481 PubMed Google Scholar

Rousselot P, Charbonnier A, Cony-Makhoul P. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronicphase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014; 32(5):424-430. https://doi.org/10.1200/JCO.2012.48.5797 PubMed Google Scholar Elias F, Gebran A, Said C, Beker RV, Ammar W.. Budget impact of treatment-free remission in treating chronic-phase Philadelphiapositive chronic myeloid leukemia in lebanon. J Glob Oncol. 2019; 5:1-7. https://doi.org/10.1200/JGO.19.00012 PubMed PubMed Central Google Scholar

A mostly great pair of speakers with an equally great price tag

Enter the nationality of the Means of Transport declared at departure. Refer to the List of Country Codes in Part 1 of the Tariff. Box 18 may be omitted in certain circumstances with the details subsequently recorded in Box 55. There are no current plans for this field to be used in the UK. Completing this box will result in the declaration going into the ‘Arrival reported’ state, and will require an ‘Arrived’ transaction to be completed by the Customs Officer at the office of destination. Goh HG, Lin M, Fukushima T. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011; 52(5):896-904. https://doi.org/10.3109/10428194.2011.555569 PubMed Google Scholar Either ‘New Transport Means Identity’ and ‘New Transport Means Nationality’ or ‘new container number’ or both must be used when a transhipment has been declared. (See notes in other Box 55 references above). The sensitive goods code is only required when the 6 digit HS code is not enough to uniquely identify which goods ex. this heading are classified as sensitive.

a b Barrie, Douglas. "BAe offers to build new Nimrod 2000s for RAF." Flight International, 27 March 1996. Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003; 120(6):990-999. https://doi.org/10.1046/j.1365-2141.2003.04200.x PubMed Google ScholarClark RE, Polydoros F, Apperley JF. Deescalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019; 6(7):e375-e383. https://doi.org/10.1016/S2352-3026(19)30094-8 Google Scholar BAe evaluated several different engines to power the Nimrod 2000, such as the Rolls-Royce Tay turbofan, the Pratt & Whitney JT8D-200 turbofan, and the General Electric CF34 turbofan, [5] before settling upon the Rolls-Royce BR710 engine. In 1995, it was claimed that the Nimrod MR2 airframes were of a sufficient condition in that they could readily serve through the intended 25-year service life and that "retained airframe items are low risk". [6] According to BAe, the Nimrod's airframe represented "probably the best understood airframe in the RAF inventory". [3] When the RoC-Control Indicator is equal to DI, this data item is required. When the RoC-Control Indicator is equal to OT, this data item cannot be used. Enter the identity number of the arriving container if it’s different from the one shown on the TAD.